Review decision – January 2020 (TA431)
Decision to update the guidance
The company that markets mepolizumab (GSK) has requested that NICE align the mepolizumab recommendation to that for benralizumab in TA565. During the development of TA565 the committee concluded that benralizumab and mepolizumab were essentially similar in terms of their clinical and cost effectiveness.
As such, a review of TA431 will be scheduled into the work programme as a Single Technology Appraisal. Given that the committee has already concluded that benralizumab and mepolizumab have similar clinical effectiveness, a cost comparison, fast track appraisal may be appropriate should the company wish to continue down this route.
The timeline for this appraisal will be subject to the availability of the appraisal committee and will be confirmed in due course.
This page was last updated: